Aspirin to prevent blood clots in advanced germ cell cancer chemotherapy
Part of Cancer, Heart & circulation, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests if daily aspirin can prevent dangerous blood clots in people receiving chemotherapy for advanced testicular or germ cell cancer. It is for those at high risk of clots and aims to improve safety during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced testicular or germ cell cancer (stage IS, IIA or higher, including mediastinal or retroperitoneal types).
- You are about to start or have just started 3-4 cycles of cisplatin-based chemotherapy (like BEP, EP, or VIP).
- You are at high risk for blood clots (based on your cancer stage, blood markers, or a Khorana score of 2 or higher).
- You have not had a blood clot before and are not currently on blood thinners or antiplatelet drugs (except NSAIDs for pain).
- You can swallow pills and are willing to take daily aspirin for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether giving enoxaparin (a blood thinner) can prevent dangerous blood clots in people with advanced germ cell tumors starting their first chemotherapy. It is especially focused on people who are at higher risk of clots.
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
This trial checks whether a specific treatment approach works better for men with higher-risk non-seminomatous germ-cell tumors that have spread. Doctors will use tumor marker changes and where the cancer started (often the chest area) to help guide treatment choices.
Hear when a new Germ Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.